arrow
P

Pedro M. Folegatti

sanofi
H指数:27
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial

乌干达健康成人中ChAdOx1 RVF疫苗预防裂谷发热的安全性、耐受性和免疫原性: 一项单中心、单盲、随机、安慰剂对照、剂量递增、1期试验

2025-11-110
OAAI
Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study

Folegatti, P.M.; Pepin, S.; Tabar, C.; Fries, K.; Talanova, O.; See, S.; Essink, B.; Bertoch, T.; Drazan, D.; Natalini Martínez, S.; 等. 重组流感疫苗在儿童、青少年和成人中的免疫原性和安全性比较评估:一项3期免疫桥接、开放标签、非随机研究的成果。Lancet Infect. Dis. 2025. [Google Scholar] [CrossRef]

2025-05-210
PRE
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK : a dose-escalation, randomised, controlled, phase 1 trial
2024-08-018
OAAI
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
2023-08-0110
OAAI
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

两剂ChAdOx1 nCov-19 (AZD1222) 后免疫反应的持续性: 两项随机对照试验的1年随访

2023-02-028
OAAI
Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: Safety and parasite growth dynamics
2022-08-226
OAAI
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
2022-07-019
OAAI
Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR
2022-04-208
OAAI
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
2022-04-0834
OA
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

ChAdOx1 nCoV-19 (AZD1222) 疫苗对巴西流行的SARS-CoV-2谱系的功效

2021-10-0638
OAAI
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
LANCET
IF88.5
2021-09-01175
OAAI
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
2021-08-01185
OAAI
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
2021-07-3035
OAAI
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

RH5疫苗接种后人类血液阶段疟疾生长和免疫相关性降低

MED
IF11.8
2021-06-0185
OAAI
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (vol 27, pg 270, 2021)
2021-05-215
OAAI
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (vol 27, pg 279, 2021)
2021-05-066
OAAI